BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data
Go back to BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data| (NYSE: UCB) | Delayed: 34.04 +0.66 (1.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.38 | 52 Week High | $ | |||
| Open | $33.61 | 52 Week Low | $ | |||
| Day High | $34.13 | P/E | N/A | |||
| Day Low | $33.43 | EPS | $ | |||
| Volume | 1,031,696 | |||||
| UCB Unsponsored ADR (AMEX: UCBJY) | Delayed: 143.03 +1.60 (1.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $141.43 | 52 Week High | $46.25 | |||
| Open | $144.50 | 52 Week Low | $32.74 | |||
| Day High | $144.50 | P/E | N/A | |||
| Day Low | $142.08 | EPS | $0.00 | |||
| Volume | 74,721 | |||||
